Joshua Tisdell Schiffer

The paper models how delayed immune responses and prolonged infections increase the transmission risk of SARS-CoV-2 variants with fitness-enhancing mutations.

The paper models drug efficacy in rhesus macaques and humans to show differences in required plasma concentrations for antiviral activity against SARS-CoV-2.

The paper models in vivo functions of five anti-HIV bnAbs using clinical trial data to quantify neutralization, Fc-mediated killing, and resistance.

The paper uses mathematical models to analyze HHV-8 oral shedding patterns in Ugandan individuals, finding that shedding rates depend on reactivation rates and immune responses.

This study examines how HSV-2 shedding affects immune cell organization and gene expression in the vaginal mucosa, finding increased immune surveillance and potential tissue homeostasis mechanisms.

This study evaluates combinations of approved oral nucleoside analogues against multiple alphaviruses in vitro and in vivo, finding synergistic antiviral effects and reduced viral mutation rates with combination therapy.

This study models HSV-1 dynamics in epithelial and neuronal cells under low and high MOI, revealing differences in eclipse phase duration, egress rates, and productive infection kinetics.

The paper uses a statistical learning strategy to track SARS-CoV-2 Spike protein mutations in the US, identifying new variants and their spatiotemporal patterns.

This paper identifies highly-conserved CRISPR guide RNAs for HIV cure and models the impact of viral diversity on therapeutic success.

The paper reports a large genomic deletion in human coronavirus 229E associated with myeloablation in a patient undergoing hematopoietic cell transplantation.